Market LIVE
Published markets; coverage varies by country
Product profile · United States

ZYCUBO

 ·  Patent Litigation & Settlement History ↓

IngredientCOPPER HISTIDINATE
Application typeNDA
Application211241
Product001
Dosage formPOWDER
RouteSUBCUTANEOUS
Strength2.9MG/VIAL
Approval date2026-01-12
Marketing statusPrescription
Status event—
ApplicantSENTYNL THERAPS INC
Product source

Current GenericRadar decision

Year2033
SelectionCANDIDATE
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2033-01-12
Patent anchor—
Exclusivity anchor2033-01-12
Protection date2033-01-12
First Final ANDA—
Status event—

Current reviewed Cu-histidinate publications US20240139236 and US20230381222 are applications, not issued patents. A notice of allowance is not a grant. Do not adopt 2042/2043 hypothetical patent dates. Full pediatric-Menkes ODE to 2033-01-12 controls.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE—2031-01-12Active-moiety submission/approval barrier across uses.YY——Source
NCE2026-01-122031-01-12Active-moiety submission/approval barrier across uses.YY2031-01-12—Source
ODE-520—2033-01-12Pediatric Menkes disease.YY——Source
ODE-5202026-01-122033-01-12Pediatric Menkes disease.YY2033-01-12—Source

2026-10-13 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED

2026-10-10 · CURRENT_SOURCE_RECORDS_FOUND · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (3)
TypeDateRoleBasisSource
REGULATORY_EXCLUSIVITY2031-01-12SCOPE_CONTEXTActive-moiety submission/approval barrier across uses.Source
REGULATORY_EXCLUSIVITY2033-01-12CANONICAL_ANCHORPediatric Menkes disease.Source
REGULATORY_STATUS2033-01-12CANONICAL_DECISIONCurrent reviewed Cu-histidinate publications US20240139236 and US20230381222 are applications, not issued patents. A notice of allowance is not a grant. Do not adopt 2042/2043 hypothetical patent dates. Full pediatric-Menkes ODE to 2033-01-12 controls.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.